NEOPLASMA
Article List
Volume 67, 2020, No. 1
ISSN 0028-2685 (print)
ISSN 1338-4317 (online)
Content:
- Roska, J. - Jurkovicova, D.: Understanding the crosstalk of molecular factors and signaling pathways reveals novel biomarkers of cisplatin resistance in testicular germ cell tumors. (p. 1)
- Liu, X. - Tang, D. - Dai, Y. - Gao, X. - Liu, L.: PCNA and GSK3β interact with each other to regulate H1299 lung adenocarcinoma cells apoptosis. (p. 15)
- Li, M. - Liu, Y. - Xu, Y. - Li, Y. - Pan, D. - Wang, L. - Yan, J. - Wang, X. - Yang, R. - Yang, M.: Preliminary evaluation of GLP-1R PET in the diagnosis and risk stratification of pheochromocytomas. (p. 27)
- Ouyang, Y. - Jin, Y. - Chen, X. - Zhang, G. - Mao, S. - Ling, F. - Luo, W.: STIL is upregulated in nasopharyngeal carcinoma tissues and promotes nasopharyngeal carcinoma proliferation, migration and invasion. (p. 37)
- Chi, X. - Meng, X. - Ding, D. - Xuan, X. - Chen, Y. - Cai, Q. - Wang, A.: HMGA1-mediated miR-671-5p targets APC to promote metastasis of clear cell renal cell carcinoma through Wnt signaling. (p. 46)
- Ha, Y. - Dai, Y. - Wufuer, D. - Pidayi, M. - Anasihan, G. - Chen, L.: Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling. (p. 54)
- Wang, J. - Zhu, J. - Mao, D. - Zhu, S. - Mi, X. - Yu, Q.: An indel polymorphism in the 3′ untranslated region of HMGB1 confers risk for hepatocellular carcinoma by regulating HMGB1 transcriptional activity in a Chinese population. (p. 61)
- Jiang, H. - Lv, D. - Song, X. - Wang, C. - Yu, Y. - Zhao, S.: Upregulated circZMIZ1 promotes the proliferation of prostate cancer cells and is a valuable marker in plasma. (p. 68)
- Bao, Y. - Zhao, T. - Zhang, Z. - Liang, X. - Wang, Z. - Xiong, Y. - Lu, X. - Wang, L.: High eukaryotic translation elongation factor 1 alpha 1 expression promotes proliferation and predicts poor prognosis in clear cell renal cell carcinoma. (p. 78)
- Cui, Z. - Liu, Q. - Sun, S. - Jiao, K. - Liu, D. - Zhou, X. - Huang, L.: MiR-378a-5p inhibits angiogenesis of oral squamous cell carcinoma by targeting KLK4. (p. 85)
- Zuo, Y. - Zheng, W. - Liu, J. - Tang, Q. - Wang, S. - Yang, X.: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. (p. 93)
- Duan, W. - Bi, P. - Ma, Y. - Liu, N. - Zhen, X.: MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. (p. 102)
- Liu, Z. - Tian, Y. - Wu, H. - Ouyang, S. - Kuang, W.: LncRNA H19 promotes glioma angiogenesis through miR-138/HIF-1α/VEGF axis. (p. 111)
- Huang, P. - Peng, S. - Yu, H. - Huang, L. - Yao, Q. - Wang, X. - Tan, S. - Zhou, J. - Wang, P. - Huang, A. - Bai, L. - Luo, Y. - Huang, M.: Decreased expression of SorCS1 in colorectal cancer: An independent predictor of poor prognosis. (p. 119)
- Liu, S. - Zhou, L. - Wang, H. - Li, G. - Xie, Q. - Hu, B.: Loss of IGF2R indicates a poor prognosis and promotes cell proliferation and tumorigenesis in bladder cancer via AKT signaling pathway. (p. 129)
- Song, Z. - Zhang, Q. - Zhu, J. - Yin, G. - Lin, L. - Liang, C.: Identification of urinary hsa_circ _0137439 as potential biomarker and tumor regulator of bladder cancer. (p. 137)
- Liu, X. - Zhou, X. - Chen, Y. - Huang, Y. - He, J. - Luo, H.: miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs). (p. 147)
- Jakl, L. - Skorvaga, M. - Beresova, K. - Kosik, P. - Durdik, M. - Jakubikova, J. - Holop, M. - Kubes, M. - Zastko, L. - Markova, E. - Beliaev, I.: BCR/ABL preleukemic fusion gene in subpopulations of hematopoietic stem and progenitor cells from human UCB. (p. 158)
- Kalfert, D. - Ludvikova, M. - Kholova, I. - Ludvik, J. - Topolocan, O. - Plzak, J.: Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors. (p. 164)
- Feng, X. - Nie, S. - Huang, J. - Li, T. - Zhou, J. - Wang, W. - Zhuang, L. - Meng, F.: Circular RNA circHIPK3 serves as a prognostic marker to promote chronic myeloid leukemia progression. (p. 171)
- Stork, M. - Sevcikova, S. - Brozova, L. - Spicka, I. - Maisnar, V. - Minarik, J. - Jungova, A. - Gregora, E. - Velichova, R. - Hajek, R. - Jelinek, T. - Pour, L.: Bortezomib retreatment is effective in relapsed multiple myeloma patients – real-life clinical practice data. (p. 178)
- Nayebbagher, T. - Pashaiefar, H. - Yaghmaie, M. - Alimoghaddam, K. - Jalili, M. - Esfandbod, M. - Saberian, M. - Behroozi, H. - Izadifard, M. - Ghavamzadeh, A.: Chromosomal aberrations in ascetic fluid of metastatic gastric cancer patients: A clustering analysis. (p. 185)
- Adamczyk, M. - Konkol, M. - Matecka-Nowak, M. - Piotrowski, T.: 4DCT-based evaluation of lung tumour motion during the breathing cycle. (p. 193)
- Bu, B. - Yi, K. - Wang, H. - Yang, M. - Wu, M. - Ping, L. - Xie, Y. - Qiu, J. - Zhao, L. - Mei, D. - Wang, X. - Song, Y. - Zhu, J. - Liu, W.: Hepatitis B virus infection status is not associated with poor prognosis in classical Hodgkin lymphoma patients. (p. 203)
- Bronswijk, M. - Laenen, A. - Bechter, O.: Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.. (p. 209)